Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Rational engineering of the P5 TRS-mimic site and REP78/68 start codon yields promoter variants that improve rAAV purity while maintaining high titers.

Molecular therapy. Advances·2026

Same author

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.

Cell reports·2026

Same author

Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencing.

Research square·2026

Same author

Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma.

Science translational medicine·2025

Same author

Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer.

European journal of cancer (Oxford, England : 1990)·2025

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Initial testing of dasatinib by the pediatric preclinical testing program.

E Anders Kolb¹, Richard Gorlick, Peter J Houghton

¹The Children's Hospital at Montefiore, Bronx, New York, USA. eakolb@nemours.org

Pediatric Blood & Cancer

|October 5, 2007

Summary

Dasatinib shows activity against specific cancer cell lines and a Philadelphia chromosome-positive acute lymphoblastic leukemia xenograft. This dual tyrosine kinase inhibitor demonstrated limited in vivo efficacy in solid tumors but significant anti-leukemia effects.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Experiment Videos

Last Updated: Jul 11, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Area of Science:

Pharmacology
Oncology
Molecular Biology

Background:

Dasatinib is a dual inhibitor of src and abl tyrosine kinases.
It is FDA-approved for imatinib mesylate-resistant chronic myeloid leukemia.

Purpose of the Study:

To evaluate the preclinical efficacy of dasatinib against a panel of pediatric solid tumors and leukemia xenografts.
To determine dasatinib's activity in vitro and in vivo.

Main Methods:

Dasatinib was tested in vitro against 22 cell lines from the Pediatric Preclinical Testing Program (PPTP) panel.
In vivo testing involved oral administration of dasatinib (50 mg/kg) to xenograft models.

Main Results:

Dasatinib exhibited selective in vitro activity, with IC(50) values around 10 nM for AML line Kasumi-1 and rhabdoid tumor line CHLA-266.
In vivo, dasatinib showed limited activity against solid tumor xenografts but significant efficacy against a Philadelphia chromosome-positive ALL xenograft, with complete response observed.

Conclusions:

Dasatinib demonstrates potent in vitro activity against a subset of cancer cell lines.
The drug shows promising in vivo activity against specific leukemia xenografts, particularly Ph(+) ALL, warranting further investigation.